{"prompt": "['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', '1.', 'PROTOCOL SYNOPSIS FOR STUDY 201749', 'Rationale', 'The primary purpose of this study is to demonstrate improvements in lung function in', 'subjects treated with Umeclidinium/Vilanterol (UMEC/VI) compared with Umeclidinium', '(UMEC) for 24 weeks. A further important aspect of the study is to evaluate the effect of', 'UMC/VI, UMEC, and salmeterol with respect to health-related quality of life (HRQoL),', 'measured through patient reported outcomes (PROs) questionnaires, and lung function.', 'Additional assessments to further evaluate other measures of chronic obstructive', 'pulmonary disease (COPD) efficacy and symptoms control will be performed.', 'Objective(s)/Endpoint(s)', 'Objectives', 'Enpoints', 'Primary', 'To compare the effect of UMEC/VI', 'Change from baseline in trough Forced', '(62.5/25 mcg once daily) with UMEC', 'Expiratory Volume in One Second', '(62.5 mcg once daily) on lung function', '(FEV1) at week 24', 'Secondary', 'To compare UMEC/VI (62.5/25 mcg', 'Change from baseline in self', 'once daily), UMEC (62.5 mcg once', 'administered computerised (SAC)', 'daily) with salmeterol (50 mcg twice', 'transient dyspnea index (TDI)', 'daily) on patient reported outcomes', '(PROs)', 'Percentage of TDI responders', 'according to SAC TDI score. A', 'responder is defined as a >1 unit', 'improvement in SAC TDI score', 'Assessment of respiratory daily', 'symptoms over 24 weeks using', 'Evaluating Respiratory Symptoms-', 'COPD (E-RS) and its subscales', '(breathlessness, cough and sputum and', 'chest symptoms)', 'Percentage of E-RS responders', 'according to E-RS score (defined as', 'reduction in E-RS score of >2 or >3.35', 'units) from baseline', \"Change from baseline in St George's\", 'Respiratory Questionnaire (SGRQ-C)', 'Percentage of responders according to', 'SGRQ-C total score (defined as a 4', 'point or greater reduction from', '9']['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Objectives', 'Enpoints', 'baseline)', 'Change from baseline in COPD', 'assessment test (CAT)', 'Percentage of responders according to', 'CAT (defined as a 22 unit improvement', 'in score from baseline)', 'Other', 'To compare UMEC/VI (62.5/25 mcg', 'Rate of mild, moderate or', 'severe', 'once daily), UMEC (62.5 mcg once', 'exacerbations', 'daily) with salmeterol (50 mcg twice', 'daily) on other COPD efficacy measures', 'Time to first mild, moderate or severe', 'exacerbation', 'Rate of moderate or severe', 'exacerbation', 'Time to moderate or severe', 'exacerbation', 'Time to severe exacerbations', 'Time to clinically important', 'deterioration (CID) composite endpoint', 'Time to clinically important', 'deterioration composite endpoint', 'excluding FEV1', 'Rescue albuterol/salbutamol use,', '(percentage of rescue-free days and', 'mean number of Inhalations/day)', 'captured by the electronic diary', '(eDiary) over 24 weeks', 'Inspiratory capacity (IC)', 'Full Vital capacity (FVC)', 'Change from baseline in trough FEV1', 'Change from baseline in global', 'impression of disease severity', '10']['2016N277425_00', 'CONFIDENTIAL', '2018N377698_00', '201749', 'Objectives', 'Enpoints', 'Safety', 'To evaluate safety and tolerability', 'Incidence of adverse events', 'of UMEC/VI (62.5/25 mcg once', 'daily), UMEC (62.5mcg once daily)', 'and salmeterol 50mcg twice daily)', 'Exploratory', 'To compare albuterol/salbutamol', 'Rescue albuterol/salbutamol use,', 'use captured in the eDiary with the', '(percentage of rescue-free days and', 'electronic metered dose inhaler', 'mean number of Inhalations/day)', '(eMDI) device', 'captured by the eMDI device over 24', 'weeks as data allow', 'To explore the effect of UMEC/VI', 'Change from baseline in physical', '(62.5/25 mcg once daily), UMEC', 'activity', '(62.5 mcg once daily) with', 'salmeterol (50 mcg twice daily) on', 'physical activity', 'To investigate the CID composite', 'To compare physical activity levels,', 'endpoint ability to predict short', 'ER-S, rescue medication use,', 'term outcomes', 'exacerbations and mortality in subjects', 'with and without a CID', 'Overall Design', 'This is a multi-centre, randomized, double blind, double dummy, 3-arm parallel group', 'study. Eligible subjects will be randomized in a ratio of 1:1:1 to UMEC/VI inhalation', 'R', 'powder (62.5/25 mcg once daily) administered via the ELLIPTA dry powder inhaler', '(DPI), or UMEC (62.5 mcg once daily) administered via the ELLIPTA DPI or salmeterol', '(50 mcg twice daily (BID)) administered via the DISKUSR DPI.', 'Eligible subjects at Screening will enter a run-in period for 4 weeks during which they', 'continue taking their inhaled COPD medications (excluding ICS and any exclusionary', 'medications). In addition, subjects will be provided with short acting', 'albuterol/salmeterol to be used on as needed basis (rescue medication) throughout the', 'study.', 'Subjects who experience a moderate or severe COPD exacerbation during the run-in', 'period will be deemed run-in failures. Subjects experiencing a mild exacerbation,', 'defined as worsening of symptoms that requires no treatment with antibiotics or steroids', 'and is self managed by the patient by an increase of inhaled rescue medication, will be', 'allowed to continue in the study.', 'At the randomization Visit 2 (Day 1) those subjects who successfully complete the run-in', 'period as well as meet the other pre-defined eligibility and randomization criteria will', 'discontinue their inhaled COPD medications and will be randomized to one of the 3', 'treatment arms for 24 weeks.', '11']\n\n###\n\n", "completion": "END"}